CIL appoints Frédéric Thomas as Partner to lead its French operations

CIL, the growth strategy consulting firm with offices in the US, Europe, and the UK, has hired Frédéric Thomas as Partner to lead its French operations, and be part of its Global Healthcare & Life Sciences practice.

Frédéric has extensive experience providing strategic advisory services, transactional support, and value creation strategies to private equity firms and corporations across Europe, particularly in the Life Sciences sector.

Before joining CIL, Frédéric was an Equity Partner at Roland Berger, where he played a key role in enhancing large-cap coverage within the Life Sciences sector and in developing key accounts across Europe. He also led KPMG’s Life Sciences & Health Care sector for France for six years, driving commercial due diligence and post-deal value creation initiatives.

Earlier in his career, Frédéric was a Partner at Arthur D. Little, where he led the Life Sciences practice in France, focusing on multinational pharmaceutical groups and private equity-backed healthcare businesses. His operational experience is further grounded in his seven-year tenure at Pfizer, where he managed high-performance organisational projects and business process optimisation.  Frédéric holds a MSC in Management from HEC, Paris.

Commenting on the appointment, Jon Whiteman, Managing Partner at CIL, said: “I’m thrilled to welcome Frédéric to our senior team as we set the stage for CIL’s next chapter in France. His dynamic leadership and proven ability to drive growth, combined with his deep expertise in the Life Sciences sector, make him an invaluable addition. The opportunities ahead are vast, and I’m eager to see the progress we’ll make together in this rapidly evolving market.”

Frédéric Thomas, Partner at CIL, said: “It is an exciting time to be joining CIL. As we expand our presence in France and Europe, I’m looking forward to collaborating with the talented team here to drive growth and innovation.”